Search Within

Vicky Makker

Formats
  1. Meeting Abstract (142)
  2. Journal Article (110)
  3. Review (9)
  4. Editorial (3)
  5. Book Section (2)
  6. Guidelines (1)
Groups
  1. Department of Medicine (267)
  2. GDMT, Medicine (267)
  3. Gynecologic Medicine Service (267)
  4. Gynecology Disease Management Team (267)
  5. Solid Tumor Oncology Division (267)
  6. Surgery (94)

More Groups

People
  1. Carol Aghajanian (91)
  2. Nadeem Abu-Rustum (77)
  3. Mario Leitao (49)
  4. Alexia Iasonos (47)
  5. Kaled Alektiar (45)
  6. Qin Zhou (43)

More People

Years
  1. 2025 (11)
  2. 2024 (35)
  3. 2023 (39)
  4. 2022 (36)
  5. 2021 (19)
  6. 2020 (26)

More Years

Publications
  1. Gynecologic Oncology (65)
  2. Journal of Clinical Oncology (58)
  3. International Journal of Gynecological Cancer (36)
  4. Annals of Oncology (23)
  5. Gynecologic Oncology Reports (8)
  6. Clinical Cancer Research (6)

More Publications

Publishers
  1. Elsevier Inc. (74)
  2. American Society of Clinical Oncology (61)
  3. Lippincott Williams & Wilkins (37)
  4. Oxford University Press (26)
  5. American Association for Cancer Research (12)
  6. Wiley Blackwell (9)

More Publishers

Results (267)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of stage IA polyp-limited vs endometrium-limited epithelial high grade endometrial carcinoma (EMC)
    Meeting Abstract

    Liang, L.; Perez, A. R.; Cangemi, N. A.; Zhou, Q.; Iasonos, A.; Alektiar, K. M.; Abu Rustum, N.; Makker, V.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma and advanced endometrial cancer
    Meeting Abstract

    Spoerke, J. M.; Makker, V.; Aghajanian, C.; Thomas, P.; Motzer, R. J.; Lauchle, J. O.; Parmar, H.; Gilbert, H.; Lin, W.; O'Keeffe, B.; more...
    Molecular Cancer Therapeutics (2015)

    Fulltext@MSK | Save
  • Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N
    Journal Article

    Makker, V.; Filiaci, V. L.; Chen, L. M.; Darus, C. J.; Kendrick, J. E.; Sutton, G.; Moxley, K.; Aghajanian, C.
    Gynecologic Oncology (2015)

    Fulltext@MSK | Save
  • Undifferentiated endometrial carcinomas: Where do they fit in?
    Meeting Abstract

    Schiavone, M.; Zivanovic, O.; Zhou, Q.; Soslow, R.; Leitao, M.; Alektiar, K.; Makker, V.; Iasonos, A.; Abu Rustum, N.
    Laboratory Investigation (2015)

    Fulltext@MSK | Save
  • Undifferentiated endometrial carcinomas: Where do they fit in?
    Meeting Abstract

    Schiavone, M.; Zivanovic, O.; Zhou, Q.; Soslow, R.; Leitao, M.; Alektiar, K.; Makker, V.; Iasonos, A.; Abu Rustum, N.
    Modern Pathology (2015)

    Fulltext@MSK | Save
  • Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results
    Meeting Abstract

    Makker, V.; Recio, F. O.; Ma, L.; Matutonis, U.; Lauchle, J. O.; Parmar, H.; Gilbert, H.; Wang, Y. L.; Koeppen, H.; Spoerke, J. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer: GOG-0229N
    Meeting Abstract

    Makker, V.; Filiaci, V. L.; Chen, L. M.; Darus, C.; Kendrick, J. E.; Sutton, G.; Moxley, K.; Aghajanian, C.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer
    Meeting Abstract

    Konstantinopoulos, P.; Makker, V.; Barry, W. T.; Liu, J.; Horowitz, N. S.; Birrer, M. J.; Doyle, L. A.; Berlin, S. T.; Whalen, C.; Van Hummelen, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • TRC105 (anti-endoglin antibody) in combination with bevacizumab (BEV) and as a single agent for platinum resistant ovarian cancer
    Meeting Abstract

    Garcia, A. A.; Makker, V.; Spitz, D. L.; Matei, D. E.; Nick, A. M.; Landen, C. N.; Alvarez, E. A.; Mendelson, D. S.; Strother, R. M.; Seon, B. K.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma
    Journal Article

    Desai, N. B.; Kollmeier, M. A.; Makker, V.; Levine, D. A.; Abu-Rustum, N. R.; Alektiar, K. M.
    Gynecologic Oncology (2014)

    Fulltext@MSK | Save